» Articles » PMID: 38753085

Diagnosis and Management of Primary Hyperoxalurias: Best Practices

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2024 May 16
PMID 38753085
Authors
Affiliations
Soon will be listed here.
Abstract

The primary hyperoxalurias (PH 1, 2, and 3) are rare autosomal recessive disorders of glyoxylate metabolism resulting in hepatic overproduction of oxalate. Clinical presentations that should prompt consideration of PH include kidney stones, nephrocalcinosis, and kidney failure of unknown etiology, especially with echogenic kidneys on ultrasound. PH1 is the most common and severe of the primary hyperoxalurias with a high incidence of kidney failure as early as infancy. Until the recent availability of a novel RNA interference (RNAi) agent, PH care was largely supportive of eventual need for kidney/liver transplantation in PH1 and PH2. Together with the Oxalosis and Hyperoxaluria Foundation, the authors developed a diagnostic algorithm for PH1 and in this report outline best clinical practices related to its early diagnosis, supportive treatment, and long-term management, including the use of the novel RNAi. PH1-focused approaches to dialysis and kidney/liver transplantation for PH patients with progression to chronic kidney disease/kidney failure and systemic oxalosis are suggested. Therapeutic advances for this devastating disease heighten the importance of early diagnosis and informed treatment.

Citing Articles

Synthesis and LDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria.

Rico-Molina M, Ortega-Vidal J, Molina-Canteras J, Cobo J, Altarejos J, Salido S Int J Mol Sci. 2025; 25(24.

PMID: 39769031 PMC: 11675970. DOI: 10.3390/ijms252413266.


Effect of the allelic background on the phenotype of primary hyperoxaluria type I.

Mandrile G, Cellini B, Ferraro P Curr Opin Nephrol Hypertens. 2024; 34(2):177-183.

PMID: 39641329 PMC: 11789592. DOI: 10.1097/MNH.0000000000001057.


Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory.

Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S Kidney Int Rep. 2024; 9(11):3083-3096.

PMID: 39534212 PMC: 11551133. DOI: 10.1016/j.ekir.2024.08.031.

References
1.
Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M . Pathophysiology and Management of Hyperoxaluria and Oxalate Nephropathy: A Review. Am J Kidney Dis. 2021; 79(5):717-727. DOI: 10.1053/j.ajkd.2021.07.018. View

2.
Fargue S, Bourdain C . Primary hyperoxaluria type 1: pathophysiology and genetics. Clin Kidney J. 2022; 15(Suppl 1):i4-i8. PMC: 9113437. DOI: 10.1093/ckj/sfab217. View

3.
Danpure C, Jennings P . Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 1986; 201(1):20-4. DOI: 10.1016/0014-5793(86)80563-4. View

4.
Webster K, Ferree P, Holmes R, Cramer S . Identification of missense, nonsense, and deletion mutations in the GRHPR gene in patients with primary hyperoxaluria type II (PH2). Hum Genet. 2000; 107(2):176-85. DOI: 10.1007/s004390000351. View

5.
Monico C, Rossetti S, Belostotsky R, Cogal A, Herges R, Seide B . Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol. 2011; 6(9):2289-95. PMC: 3358997. DOI: 10.2215/CJN.02760311. View